These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 8794900

  • 1. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
    Animati F, Arcamone F, Bigioni M, Capranico G, Caserini C, De Cesare M, Lombardi P, Pratesi G, Salvatore C, Supino R, Zunino F.
    Mol Pharmacol; 1996 Sep; 50(3):603-9. PubMed ID: 8794900
    [Abstract] [Full Text] [Related]

  • 2. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A, Liu LF, Israel M, Seshadri R, Koseki Y, Giuliani FC, Kirschenbaum S, Silber R, Potmesil M.
    Cancer Res; 1989 Nov 01; 49(21):5969-78. PubMed ID: 2551497
    [Abstract] [Full Text] [Related]

  • 3. Synthesis and conformational preference of novel 8-fluoroanthracyclines.
    Lombardi P, Animati F, Cipollone A, Giannini G, Monteagudo E, Arcamone F.
    Acta Biochim Pol; 1995 Nov 01; 42(4):433-44. PubMed ID: 8852334
    [Abstract] [Full Text] [Related]

  • 4. Influence of structural modifications at the 3' and 4' positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance.
    Capranico G, Supino R, Binaschi M, Capolongo L, Grandi M, Suarato A, Zunino F.
    Mol Pharmacol; 1994 May 01; 45(5):908-15. PubMed ID: 8190107
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. DNA topoisomerase II as the primary target of anti-tumor anthracyclines.
    Zunino F, Capranico G.
    Anticancer Drug Des; 1990 Nov 01; 5(4):307-17. PubMed ID: 1963303
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Interaction model for anthracycline activity against DNA topoisomerase II.
    Moro S, Beretta GL, Dal Ben D, Nitiss J, Palumbo M, Capranico G.
    Biochemistry; 2004 Jun 15; 43(23):7503-13. PubMed ID: 15182192
    [Abstract] [Full Text] [Related]

  • 14. Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.
    Fang L, Zhang G, Li C, Zheng X, Zhu L, Xiao JJ, Szakacs G, Nadas J, Chan KK, Wang PG, Sun D.
    J Med Chem; 2006 Feb 09; 49(3):932-41. PubMed ID: 16451059
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L, Hansen HF, Wessel I, Nitiss JL, Schmidt G, Jensen PB, Sehested M, Jensen LH.
    Anticancer Drug Des; 2001 Dec 09; 16(6):305-15. PubMed ID: 12375883
    [Abstract] [Full Text] [Related]

  • 20. Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts.
    Pratesi G, De Cesare M, Caserini C, Perego P, Dal Bo L, Polizzi D, Supino R, Bigioni M, Manzini S, Iafrate E, Salvatore C, Casazza A, Arcamone F, Zunino F.
    Clin Cancer Res; 1998 Nov 09; 4(11):2833-9. PubMed ID: 9829750
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.